ReviewTherapeutic advances in medical oncology2024

Expert consensus on the use of third-generation EGFR-TKIs in EGFR-mutated advanced non-small cell lung cancer with various T790M mutations post-resistance to first-/second-generation EGFR-TKIs.

Jietao Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.